| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Simpson Andrew | Chairman of the Board, President and Chief Executive Officer, Director | C/O HEARTSCIENCES INC.,, 550 RESERVE STREET, SUITE 360, SOUTHLAKE | /s/ Andrew Simpson | 11 Jul 2025 | 0001933883 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HSCS | Stock Option (Right to Buy) | Award | +275,000 | 275,000 | 09 Jul 2025 | Common Stock | 275,000 | $4.37 | Direct | F1, F2, F3 | |||
| transaction | HSCS | Restricted Stock Units | Award | $0 | +68,750 | $0.000000 | 68,750 | 09 Jul 2025 | Common Stock | 68,750 | $0.000000 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | These options were granted to the Reporting Person effective as of July 9, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors. |
| F2 | One-third of the options shall vest on the 12-month anniversary of the Effective Date, with an additional 8.333% of the options vesting on each of October 9, 2026 and thereafter on each successive three-month anniversary of such date, such that all options shall vest on July 9, 2028 (or earlier as described below), subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date and subject to the terms of the Plan. These options shall become fully-vested and may be exercised at any time at the Reporting Person's election upon the Issuer receiving regulatory clearance for its MyoVista wavECG device or AI-ECG algorithm (subject to certain requirements) (or similar such product owned by the Issuer) from the U.S. Food and Drug Administration, or a Change of Control (as defined in the Reporting Person's Employment Agreement (the "EA")). As of the date of this filing, such regulatory clearance has not been received. |
| F3 | These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Equity Incentive Plan, as amended (the "Plan") or the underlying options grant agreement. |
| F4 | Represents Restricted Stock Units (the "RSUs") granted to the Reporting Person pursuant to the approval of the compensation committee of the Issuer's board of directors. The RSUs shall vest immediately upon the earlier of (i) FDA clearance of MyoVista Device (including AI algorithm) or (ii) the MyoVista Insights platform together with first AI algorithm, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date and subject to earlier full vesting upon a Change of Control (as defined in the EA) or such other earlier vesting acceleration conditions as provided in the EA. Each vested RSU shall be settled by delivery to the Reporting Person of one share of the Issuer's common stock on the first to occur of: (i) promptly after the applicable vesting date, (ii) the date of a Change of Control or (iii) such other earlier settlement as provided in the EA. |
Chairman of the Board, President and Chief Executive Officer